ArticleHuman vaccines & immunotherapeutics2022
Capacity Building for Vaccine Manufacturing Across Developing Countries: The Way Forward.
Article in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- MPOX outbreak in Africa: the urgent need for local manufacturing of the vaccine and decolonized health systems.BMC public health · 2025Pooled it
- Association of gross domestic product with equitable access to childhood vaccines in 195 countries: a systematic review and meta-analysis.BMJ global health · 2025Pooled it
- Developing an Evidence-Informed Strategic Framework for Veterinary Vaccine Manufacturing Modernization Toward PIC/S GMP Compliance.Vaccines · 2026Article
- Article
- Bridging the gap: the Pasteur Network's approach to equitable vaccine development and manufacturing.BMC global and public health · 2026Review
- Review
- Catalysing vaccines research, development and manufacturing in Nigeria: a qualitative exploration of industry stakeholders' knowledge, perceptions and experience.Health research policy and systems · 2026Article
- Participation pathways in global vaccine partnerships and their implications for immunization systems: a comparative analysis of China and India in Gavi.Frontiers in public health · 2026Article
- Africa is an Essential Partner in the Research and Development of an HIV Vaccine.Current HIV research · 2026Review
- Nigeria's post-COVID-19 vaccine manufacturing ambitions: Opportunities and regional implications.Journal of public health in Africa · 2026Article
- GenIV vaccines: bridging innovation to equity in neglected tropical diseases.Frontiers in immunology · 2026Review
- From proposal to compromise: the TRIPS waiver debate and the crisis of WTO decision-making.Globalization and health · 2025Review
- Review
- Overcoming barriers to medical countermeasures: Strengthening global biosecurity.Human vaccines & immunotherapeutics · 2025Review
- The long-term impact of vaccine clinical research on national stakeholders involved: Experience from a low-income Country.Human vaccines & immunotherapeutics · 2025Article
- Strengthening New Vaccine Introduction in Low- and Middle-Income Countries: Establishing Hospital-Based Sentinel Surveillance for Vaccine Safety Monitoring.The American journal of tropical medicine and hygiene · 2025Article
- The Silent Risk of Sudan Virus: A Review Addressing Global Health Vulnerabilities.Health science reports · 2025Article
- Theranostics in nuclear medicine: the era of precision oncology.Medical oncology (Northwood, London, England) · 2025Review
- Breaking barriers: a qualitative study on polio vaccine hesitancy in Herat Province, Afghanistan.BMC public health · 2025Article
- Opportunities and challenges of conducting vaccine research in low and middle-income countries in the Asia-Pacific region: perspectives from the Asia-Pacific Vaccine Research Network.The Lancet regional health. Western Pacific · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approved vaccines prevent 2 to 3 million deaths per year. There is a lack of equitable access to vaccines in the low- and middle-income developing nations. Challenges in the life cycle of vaccine production include process development, lead time, intellectual property, and local vaccine production. A robust and stable manufacturing process and constant raw material supplies over decades is critical. In a continuously evolving vaccine landscape, the need of the hour for developing nations is to manufacture their own vaccines besides having supply security, control over production scheduling and sustainability, control of costs, socio-economic development, and rapid response to local epidemics. There is a need for capacity building of workforce development, technology transfer, and financial support. Technology transfer has improved vaccine access and reduced prices of vaccines. Capacity building for the manufacturing of vaccines in developing countries has always been an area of paramount importance and more so in a pandemic situation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.